Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1MN gp160 recombinants followed by boosting with HIV-1SF2 gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HI...

Full description

Saved in:

Bibliographic Details
Published in:	Nature medicine Vol. 3; no. 6; pp. 651 - 658
Main Authors:	Lubeck, Michael D, Natuk, Robert, Myagkikh, Maria, Kalyan, Narender, Aldrich, Kristine, Sinangil, Faruk, Alipanah, Shabnam, Murthy, Shri C.S, Chanda, Pranab K, Nigida, Stephen M, Markham, Phillip D, Zolla-pazner, Susan, Steimer, Kathy, Wade, Mark, Reitz, Marvin S, Arthur, Larry O, Mizutani, Satoshi, Davis, Alan, Hung, Paul P, Gallo, Robert C, Eichberg, Jorg, Robert-Guroff, Marjorie
Format:	Journal Article
Language:	English
Published:	United States 01-06-1997
Subjects:	Adenoviridae - immunology AIDS/HIV Animals Female HIV Envelope Protein gp120 - immunology HIV Envelope Protein gp160 - immunology HIV Infections - immunology HIV Infections - prevention & control HIV-1 - pathogenicity Pan troglodytes Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - immunology T-Lymphocytes, Cytotoxic - physiology Vaccination - methods Vaccines - administration & dosage
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1MN gp160 recombinants followed by boosting with HIV-1SF2 gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to low-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	1078-8956 1546-170X
DOI:	10.1038/nm0697-651